Last reviewed · How we verify
Acetylcysteine 2% solution
N-acetylcysteine is a mucolytic agent that works by breaking disulfide bonds in mucus
N-acetylcysteine is a mucolytic agent that works by breaking disulfide bonds in mucus Used for Treatment of acetaminophen overdose, Mucolytic therapy for cystic fibrosis.
At a glance
| Generic name | Acetylcysteine 2% solution |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Mucolytic agent |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 1 |
Mechanism of action
It does this by donating cysteine groups to the mucus, which then breaks down the disulfide bonds, making the mucus thinner and easier to expel.
Approved indications
- Treatment of acetaminophen overdose
- Mucolytic therapy for cystic fibrosis
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome (PHASE2)
- PK and PD Study of NPI-001 and Cysteamine Bitartrate (PHASE1, PHASE2)
- Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis. (NA)
- N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome (EARLY_PHASE1)
- N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients (PHASE2)
- Ameliorating Contrast Induced Nephropathy After Coronary Angiography (PHASE4)
- A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus (NA)
- N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetylcysteine 2% solution CI brief — competitive landscape report
- Acetylcysteine 2% solution updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI